We are open as normal during COVID-19 pandemic. Order online, same day shipping out from North Carolina, USA

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318351

CAS#: 121679-13-8

Description: Naratriptan is a triptan drug marketed by GlaxoSmithKline and is used for the treatment of migraine headaches. Naratriptan is available in 2.5 mg tablets. It is a selective 5-HT1 receptor subtype agonist.

Price and Availability

Size Price Shipping out time Quantity
10mg USD 210 2 Weeks
50mg USD 490 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-08-09. Prices are subject to change without notice.

Naratriptan, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 318351
Name: Naratriptan
CAS#: 121679-13-8
Chemical Formula: C17H23N3O2S
Exact Mass: 333.1511
Molecular Weight: 333.4484
Elemental Analysis: C, 61.23; H, 6.95; N, 12.60; O, 9.60; S, 9.62

Synonym: UNII QX3KXL1ZA2; UNIIQX3KXL1ZA2; UNII-QX3KXL1ZA2; Naratriptan; Amerge; Colatan

IUPAC/Chemical Name: N-methyl-2-(3-(1-methyl-1,2,3,4-tetrahydropyridin-4-yl)-1H-indol-5-yl)ethanesulfonamide


InChi Code: InChI=1S/C17H23N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-5,8,11-12,14,18-19H,6-7,9-10H2,1-2H3


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Tfelt-Hansen PC. Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the GSK Trial Register. J Headache Pain. 2011 Aug;12(4):399-403. doi: 10.1007/s10194-011-0327-3. Epub 2011 Mar 25. Review. PubMed PMID: 21437713; PubMed Central PMCID: PMC3139062.

2: Lambert GA. Preclinical neuropharmacology of naratriptan. CNS Drug Rev. 2005 Autumn;11(3):289-316. Review. PubMed PMID: 16389295.

3: Dulli DA. Naratriptan: an alternative for migraine. Ann Pharmacother. 1999 Jun;33(6):704-11. Review. PubMed PMID: 10410185.

4: Salonen R. Naratriptan. Int J Clin Pract. 1999 Oct-Nov;53(7):552-6. Review. PubMed PMID: 10692743.

5: Massiou H. Naratriptan. Curr Med Res Opin. 2001;17 Suppl 1:s51-3. Review. PubMed PMID: 12463278.

6: Law S, Derry S, Moore RA. Naproxen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2013 Oct 20;10:CD009455. doi: 10.1002/14651858.CD009455.pub2. Review. PubMed PMID: 24142263.

7: Tfelt-Hansen P. Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment. J Headache Pain. 2007 Oct;8(5):273-6. Epub 2007 Oct 23. Review. PubMed PMID: 17955173; PubMed Central PMCID: PMC3476154.

8: Kunkel M. [Naratriptan. A new medical option for the pharmacist]. Med Monatsschr Pharm. 2007 May;30(5):184-6. Review. German. PubMed PMID: 17526395.

9: Becker WJ. Acute Migraine Treatment in Adults. Headache. 2015 Jun;55(6):778-93. doi: 10.1111/head.12550. Epub 2015 Apr 15. Review. PubMed PMID: 25877672.

10: Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan;55(1):3-20. doi: 10.1111/head.12499. Review. PubMed PMID: 25600718.

11: Silberstein S, Patel S. Menstrual migraine: an updated review on hormonal causes, prophylaxis and treatment. Expert Opin Pharmacother. 2014 Oct;15(14):2063-70. doi: 10.1517/14656566.2014.947959. Epub 2014 Aug 6. Review. PubMed PMID: 25100506.

12: Hu Y, Guan X, Fan L, Jin L. Triptans in prevention of menstrual migraine: a systematic review with meta-analysis. J Headache Pain. 2013 Jan 30;14:7. doi: 10.1186/1129-2377-14-7. Review. PubMed PMID: 23565873; PubMed Central PMCID: PMC3620011.

13: Millson DS. Rational migraine management: optimising treatment with the triptans. Funct Neurol. 2000;15 Suppl 3:182-91. Review. PubMed PMID: 11200789.

14: Belvis R, Mas N, Aceituno A. Migraine attack treatment : a tailor-made suit, not one size fits all. Recent Pat CNS Drug Discov. 2014 Apr;9(1):26-40. Review. PubMed PMID: 24605940.

15: Nguyen TQ, Lewis JH. Sumatriptan-associated ischemic colitis: case report and review of the literature and FAERS. Drug Saf. 2014 Feb;37(2):109-21. doi: 10.1007/s40264-013-0134-7. Review. PubMed PMID: 24442762.

16: Wellington K, Jarvis B. Spotlight on rizatriptan in migraine. CNS Drugs. 2002;16(10):715-20. Review. PubMed PMID: 12269863.

17: Wellington K, Plosker GL. Rizatriptan: an update of its use in the management of migraine. Drugs. 2002;62(10):1539-74. Review. PubMed PMID: 12093318.

18: Becker WJ. The premonitory phase of migraine and migraine management. Cephalalgia. 2013 Oct;33(13):1117-21. doi: 10.1177/0333102412437390. Epub 2012 Feb 15. Review. PubMed PMID: 22337860.

19: Worthington I, Pringsheim T, Gawel MJ, Gladstone J, Cooper P, Dilli E, Aube M, Leroux E, Becker WJ; Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013 Sep;40(5 Suppl 3):S1-S80. Review. PubMed PMID: 23968886.

20: Reddy DS. The pathophysiological and pharmacological basis of current drug treatment of migraine headache. Expert Rev Clin Pharmacol. 2013 May;6(3):271-88. doi: 10.1586/ecp.13.14. Review. PubMed PMID: 23656340.